ArticlePolymers2026
Cellulose Acetate/Hydroxyapatite-Dexamethasone Loaded Membranes for the Prevention of Implant-Associated Acute Inflammation.
Article in Polymers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Implant-associated acute inflammation remains a major challenge in orthopedic, dental, and maxillofacial applications, often impairing osseointegration and leading to early implant failure. In this study, multifunctional cellulose acetate/hydroxyapatite-dexamethasone (CA/HA-DEXA) composite membranes were developed to locally modulate inflammation while supporting early bone-implant interactions. Cellulose acetate provides a flexible matrix, hydroxyapatite enhances bioactivity and osteoconductivity, and dexamethasone acts as an anti-inflammatory agent. The membranes exhibited composition-dependent swelling and drug release behavior. The swelling degree decreased from ~11% for pristine CA to ~5% for the highest HA-DEXA loading, indicating a denser structure with restricted water uptake. Dexamethasone release showed a biphasic profile, with cumulative release reaching ~68%, ~88%, and ~93% for 0.5%, 1%, and 2% HA-DEXA loadings after 72 h, respectively. In vitro evaluation indicated improved biomineralization for CA/HA-DEXA membranes compared to neat CA, attributed to the role of hydroxyapatite as a nucleation promoter. These findings suggest that CA/HA-DEXA composite membranes represent a promising strategy for controlling early inflammatory responses while supporting bone regeneration at the implant interface.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.